Clinical trials: Migraine, Acute
Migraine
Diphenhydramine for Acute Migraine
Parenteral diphenhydramine is commonly used as adjuvant therapy for acute migraine despite the fact that data supporting this practice do not exist.
- Trial name
- NCT01825941
- Testing
- metoclopramide, diphenhydramine
- Where
- United States
- Volunteers
- 208 people
- Sponsor
- Montefiore Medical Center
Migraine Disorders
An Open-label, Long-term, Safety Study of Lasmiditan for the Acute Treatment of Migraine
This is a prospective, randomized, open-label study in subjects with migraine who have completed the Phase 3 studies, COL MIG 301/LAHJ (NCT02439320) or COL MIG-302/LAHK (NCT02605174) or for a subset of lasmiditan-naïve subjects…
- Trial name
- GLADIATOR (NCT02565186)
- Testing
- Lasmiditan
- Where
- 196 sites in United States, Germany and 1 more
- Volunteers
- 2,171 people
- Sponsor
- Eli Lilly and Company
Episodic Migraine, Chronic Migraine
i-NEED: NEw migrainE Drugs Database
Approved by the Food and Drug Administration (FDA) and the European Medicine Agency (EMA) starting in 2018, anti-CGRP monoclonal antibodies (anti-CGRP mAbs) represent the first true revolution in the preventive treatment of…
- Conditions
- Episodic Migraine, Chronic Migraine, Medication Overuse Headache
- Trial name
- i-NEED (NCT07103694)
- Testing
- anti-CGRP monoclonal antibodies, gepants, combination of sumatriptan and naproxen
- Where
- 2 sites in Italy
- Volunteers
- 2,641 people
- Sponsor
- IRCCS San Raffaele Roma
Acute Migraine
DFN-02 Open Label Safety Study in Patients With Acute Migraine
A multi-center, open-label, safety study of DFN-02 for the Treatment of Acute Migraines
- Trial name
- NCT02279082
- Testing
- DFN-02
- Where
- 24 sites in United States
- Volunteers
- 167 people
- Sponsor
- Dr. Reddy's Laboratories Limited
Migraine Disorders
BI 44370 TA in Acute Migraine Attack
The objective of this trial is to assess the safety, tolerability, and efficacy of three doses of BI 44370 TA in the treatment of patients with an acute migraine attack and headache pain of moderate or severe intensity, compared…
- Trial name
- NCT00751803
- Testing
- BI 44370 TA Low Dose, Eletriptan, BI 44370 TA Medium Dose
- Where
- 52 sites in Belgium, El Salvador and 7 more
- Volunteers
- 416 people
- Sponsor
- Boehringer Ingelheim
Migraine
Efficacy and Tolerability of Zolmitriptan Nasal Spray
The purpose of this study is to evaluate the effectiveness and tolerability (the ability not to experience ill effects from the study drug) of a zolmitriptan nasal spray, 5.0 mg, compared with placebo (inactive drug) for 2…
- Trial name
- NCT00617747
- Testing
- Zolmitriptan
- Volunteers
- 2,114 people
- Sponsor
- AstraZeneca
Migraine, Tension-Type Headache
Carotid Sinus Massage in Trendelenburg Position for Headache Relief
Headaches significantly impact patients' quality of life, with tension-type headaches and migraines being among the most prevalent types.
- Trial name
- NCT06745648
- Testing
- Arm A - Carotid Sinus Massage + Trendelenburg (CSM+T)
- Where
- Argentina
- Volunteers
- 18 people
- Sponsor
- Hospital Municipal Pedro T. Orellana
Migraine
A Study to Learn About Zavegepant as the Acute Treatment of Migraine in Asian Adults
The purpose of this study is to learn how safe and effective zavegepant is compared to placebo in the acute treatment of migraine in Asian adults.
- Trial name
- NCT05989048
- Testing
- Zavegepant
- Where
- 61 sites in China, South Korea and 1 more
- Volunteers
- 1,414 people
- Sponsor
- Pfizer
Migraine With Aura
Efficacy and Safety of TMS for the Preemptive Treatment of Migraine With Aura
Assess safety and efficacy of Transcranial Magnetic Stimulation (TMS) for the treatment of migraine with aura The hypothesis is that TMS treatments delivered to the occipital cortex of the brain can stop or interrupt the…
- Trial name
- NCT00449540
- Testing
- Active Transcranial Magnetic Stimulation (TMS) Device
- Where
- 14 sites in United States
- Volunteers
- 201 people
- Sponsor
- Neuralieve
Migraine Disorders
A Study of Lasmiditan in Participants With Migraine
The purpose of this study is to measure how much of the drug gets into the blood stream and how long it takes the body to get rid of it during an acute migraine attack and also during the time between acute migraine attacks.
- Trial name
- NCT03247790
- Testing
- Lasmiditan
- Where
- 3 sites in United States
- Volunteers
- 16 people, healthy volunteers welcome
- Sponsor
- Eli Lilly and Company
Migraine
Acute Treatment of Migraine Using the CEFALY Device
The purpose of this study is to investigate the efficacy of e-TNS with the Cefaly® device as an acute treatment for a migraine attack.
- Trial name
- NCT02411513
- Testing
- CEFALY
- Where
- United States
- Volunteers
- 30 people
- Sponsor
- Cefaly Technology
Migraine
Consistency of Response With Rimegepant in Acute Treatment of Migraine
This is a non-interventional, prospective study that will enroll participants with migraine in the United Kingdom currently in use of rimegepant to acutely treat migraine attacks.
- Trial name
- CORRELATE-UK (NCT06898047)
- Testing
- Rimegepant for acute migraine treatment
- Where
- United Kingdom
- Volunteers
- 250 people
- Sponsor
- Pfizer
Acute Migraine
A Study to Evaluate the Efficacy and Tolerability of Rizatriptan for Treatment of Acute Migraine (0462-087)
A study to provide evidence supporting the benefit of Rizatriptan in patients who have an inadequate response to sumatriptan.
- Trial name
- NCT00894556
- Testing
- rizatriptan, Comparator: Sumatriptan
- Volunteers
- 109 people
- Sponsor
- Organon and Co
Headache, Migraine
Ubrogepant treatmeNt in mIgraine Patients Utilizing mOnoclonal aNtibodies
This is a prospective open-label randomized study assessing similar endpoints included in the pivotal trial for ubrogepant, which are pain freedom and freedom from the most bothersome symptom at two hours.
- Trial name
- UNION (NCT05503082)
- Testing
- Ubrogepant 50 MG [Ubrelvy], Ubrogepant 100 MG [Ubrelvy]
- Where
- 2 sites in United States
- Volunteers
- 164 people
- Sponsor
- Chicago Headache Center & Research Institute
Migraine
Study to Assess the Real-World Effectiveness of Ubrogepant in Adult Participants When Treating During the Prodrome Phase of Migraine Attacks
Migraine is a neurological disease characterized by moderate or severe headaches, associated with nausea, vomiting, and/or sensitivity to light and sound.
- Trial name
- PHASES (NCT07310290)
- Where
- 3 sites in United States
- Volunteers
- 189 people
- Sponsor
- AbbVie
Migraine
Study to Assess the Safety, Tolerance and Efficacy of Tezampanel in Patients With Acute Migraine
To evaluate the effects of a single sc administration of TEZAMPANEL at one of three different dosage levels compared to placebo, employing traditional measures of efficacy and safety in the treatment of a single episode of acute…
- Trial name
- NCT00567086
- Testing
- TEZAMPANEL
- Where
- United States
- Volunteers
- 306 people
- Sponsor
- TorreyPines Therapeutics
Migraine
Efficacy of Zolmitriptan (Zomig) in the Treatment of Migraines in Adolescents
The purpose of this study is to evaluate the effectiveness and safety of Zolmitriptan (Zomig) nasal spray, 5.0 mg, compared with placebo (inactive drug) for 2 migraine headaches over a 3-month period in adolescent patients (aged…
- Trial name
- NCT00617695
- Testing
- Zolmitriptan
- Volunteers
- 247 people
- Sponsor
- Impax Laboratories, LLC
Migraine Disorders, Migraine
An Adaptive Design Trial Of GW274150 In The Treatment Of Acute Migraine
Nitric oxide (NO) is likely to be involved in the development of migraine headache. Nitric oxide synthase (NOS) is an important chemical involved in the production of NO.
- Trial name
- NCT00319137
- Testing
- GW274150
- Where
- 5 sites in Australia, New Zealand
- Volunteers
- 126 people
- Sponsor
- GlaxoSmithKline
Migraine
Efficacy and Safety of Rizatriptan-Naproxen (10/550 mg) in the Acute Treatment of Migraine
A phase III study, multicenter, double-blind, double-dummy, randomized, single-dose, placebo-controlled study to evaluate the efficacy and safety of Rizatriptan-Naproxen (10/550 mg) in the acute treatment of migraine.
- Trial name
- RELIEF (NCT04384367)
- Testing
- Rizatriptan 10 mg + Naproxen 550mg, Maxalt 10Mg Tablet, Flanax 550mg
- Where
- 2 sites in Brazil
- Volunteers
- 2,068 people
- Sponsor
- Eurofarma Laboratorios S.A.
Episodic Migraine
Study to Assess Adverse Events When Ubrogepant Tablets in Combination With Atogepant Tablets Are Used to Treat Adult Participants With Migraine
Migraine is a neurological disease characterized by moderate or severe headache, associated with nausea, vomiting, and/or sensitivity to light and sound.
- Trial name
- TANDEM (NCT05264129)
- Testing
- Atogepant, Ubrogepant
- Where
- 37 sites in United States
- Volunteers
- 263 people
- Sponsor
- AbbVie